Abzu
Martin Kerr has a strong background in scientific research and business development within the pharmaceutical industry. Currently, Martin is focused on building partnerships with pharma and biotech companies to enhance drug discovery using explainable AI at Abzu. Prior to this role, Martin held positions at NATA, MRC Laboratory of Molecular Biology, and the University of Oxford where Martin developed strategic partnerships with pharma and biotech organizations. Martin has also worked on projects related to oligonucleotide drug design, disease understanding through multi-omic analyses, and Epithelial Growth Factor signaling in Drosophila development.
This person is not in any teams
This person is not in any offices
Abzu
14 followers
Abzu was born from a desire to challenge the fundamental assumptions of contemporary AI, believing that the future of AI lies in the more lifelike simulation of self-organizing systems. Abzu’s pioneering machine learning technology is inspired by quantum mechanics and neural networks, resulting in a transparent and trustworthy AI. Founded in January 2018, Abzu is an applied research startup with offices in Copenhagen, Denmark and Barcelona, Spain.